In retrospect, the timing of this year's PCR (Paris Course on Revascularization) meeting couldn't have been better. Held in late May, PCR offered interventional cardiologists from all over the world insights into the near-term future of drug-eluting stents (DES), from both a theoretical and a practical perspective with the first data from an important clinical trial and real-world opinions from European cardiologists who have had the new stent commercially available since its European approval in early April.
There are certainly other hot topics in cardiovascular medicine—PCR featured sessions on vulnerable plaque, angio- and myogenesis, and cardiovascular imaging—and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?